Xifaxan's Expanded Indication Comes With Additional Safety, Efficacy Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
After drug gains approval to prevent recurrence of hepatic encephalopathy, Salix plans studies in patients with end-stage liver disease and in patients not taking lactulose.